TY - JOUR T1 - Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension JF - European Respiratory Journal JO - Eur Respir J SP - 283 LP - 286 DO - 10.1183/09031936.00044915 VL - 46 IS - 1 AU - Yuichi Tamura AU - Mai Kimura AU - Makoto Takei AU - Tomohiko Ono AU - Masataka Kuwana AU - Toru Satoh AU - Keiichi Fukuda AU - Marc Humbert Y1 - 2015/07/01 UR - http://erj.ersjournals.com/content/46/1/283.abstract N2 - During the past decade, the prognosis of patients with pulmonary hypertension (PH) has improved due to the development of pulmonary arterial vasodilators [1]. Yet, treatment for right-sided heart failure (RHF) associated with PH has not improved, despite being the most important prognostic factor for chronic RHF [2, 3]. Existing treatment strategies for RHF associated with PH are restricted to administration of loop diuretics and inotropes [4]; however, administration of high doses of loop diuretics may worsen the outcome of chronic heart failure [5, 6]. In recent years, tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, has been developed for the treatment of hyponatraemia [7], autosomal dominant polycystic kidney disease [8] and heart failure. Used in addition to standard therapy that includes diuretics, tolvaptan improves many signs and symptoms of heart failure without serious adverse events [9]. However, there is no report describing the effect of tolvaptan on RHF, independent of left-sided heart disease.Vasopressin receptor antagonist tolvaptan achieved furosemide reductions and right heart failure improvements in PH http://ow.ly/LopejThe authors acknowledge the medical staff of the Dept of Cardiology, Keio University Hospital, Tokyo, Japan, for completion of medical records. ER -